References
- Braunschweiger P.G., Jones S., Johnson C., Furmanski P. Interleukin-1α-induced tumour pathophysiologies can be exploited with bioreductive alkylating agents. International Journal of Radiation Biology 1991; 60: 367–370
- Brown, J.M. Exploitation of bioreductive agents with vasoactive drugs. Proceedings of the 8th International Congress of Radiation Research Proceedings of the 8th International Congress of Radiation ResearchEdinburghUKE.M. Fielden, et al. Taylor & Francis, London 1987; 719–724
- Brown J.M. Hypoxic cell radiosensitizers: Where next?. International Journal of Radiation Oncology, Biology, Physics 1989; 16: 987–993
- Brown J.M., Koong A. The therapeutic advantage of hypoxic cells in tumors: a theoretical study. Journal of the National Cancer Institute 1991; 81: 178–185
- Brown J.M., Lemmon M.J. SR 4233: A tumor specific radiosensitizer active in fractionated radiation regimes. Radiotherapy and Oncology 1991a; 20: 151–156
- Brown J.M., Lemmon M.J. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. International Journal of Radiation Oncology, Biology, Physics 1991b; 20: 457–461
- Brown J.M., Lemmon M.J. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Research 1990; 50: 7745–7749
- Chaplin D.J. Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxy-tryptamine (5-HT). British Journal of Cancer 1986; 54: 727–731
- Chaplin D.J., Acker B. The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain. International Journal of Radiation Oncology, Biology, Physics 1987; 13: 579–585
- Edwards H.S., Bremner J.C.M., Stratford I.J. Induction of hypoxia in the KHT sarcoma by tumour necrosis factor and flavone acetic acid. International Journal of Radiation Biology 1991; 59: 419–432
- Hill R.P. Sensitizers and radiation dose fractionation: results and interpretations. International Journal of Radiation Oncology, Biology, Physics 1986; 12: 1049–1054
- Kerr D.J., Maughan T., Newlands E., Rustin G., Bleehen N.M., Lewis C. Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma. British Journal of Cancer 1989; 60: 104–106
- Rowell N.P., Flower M.A., McCready V.R., Cronin B., Horwich A. The effects of single dose oral hydralazine on blood flow through human lung tumors. Radiotherapy and Oncology 1990; 18: 283–292
- Sun J.R., Brown J.M. Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma. Cancer Research 1989; 49: 5664–5670